Loading...
•
Jun 30, 2023
Zomedica Q2 2023 Earnings Report
Reported record revenue with strong gross margins and liquidity.
Key Takeaways
Zomedica reported a 43% increase in revenue to $6.0 million for Q2 2023, driven by growth in both therapeutic and diagnostic segments. The company maintained a strong gross margin of 67% and ended the quarter with $142.4 million in cash, cash equivalents, and available for sale securities.
Revenue increased by 43% to $6.0 million compared to Q2 2022.
Therapeutic segment revenue reached $5.8 million, a 38% increase year-over-year.
Diagnostic segment revenue nearly doubled compared to Q2 2022, reaching $0.2 million.
The company ended the quarter with $142.4 million in cash, cash equivalents, and available for sale securities.
Revenue by Segment
Forward Guidance
Zomedica anticipates building on its growth trajectory by introducing new product platforms into the market in 2023 and evaluating strategic business development and M&A opportunities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...